Glycation News and Research

RSS

Exercise benefits influenced by sRAGE levels in diabetes

Increased levels of the soluble form of the receptor for advanced glycation end products may underly the beneficial effects of exercise in patients with Type 2 diabetes, research shows.

3 Aug 2012

Data supports links between AD and diabetes: New study

Alzheimer's disease is the sixth leading cause of death in the United States and the only cause of death among the top 10 in America without a way to prevent, cure or even slow its progression, according to the Alzheimer's Association. Today, 5.4 million Americans are living with the disease, and another American develops it every 69 seconds.

28 Mar 2012

New RAGE inhibitor shows promise against Alzheimer's

Researchers have taken another crack at a promising approach to stopping Alzheimer's disease that encountered a major hurdle last year. In research published this week in the Journal of Clinical Investigation, scientists have developed a compound that targets a molecular actor known as RAGE, which plays a central role in mucking up the brain tissue of people with the disease.

15 Mar 2012

Researchers discover one of vitamin E's normal body functions

It's rubbed on the skin to reduce signs of aging and consumed by athletes to improve endurance but scientists now have the first evidence of one of vitamin E's normal body functions.

21 Dec 2011

Lower glycemic index diet may delay onset of AMD-like lesions

Feeding older mice a lower glycemic index (GI) diet consisting of slowly-digested carbohydrates delays the onset of age-related, sight-threatening retinal lesions, according to a new study from the Laboratory for Nutrition and Vision Research at the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University.

14 Nov 2011

'Ultra-bad' cholesterol increases risk of heart disease in people with type 2 diabetes

Scientists from the University of Warwick have discovered why a newly found form of cholesterol seems to be 'ultra-bad', leading to increased risk of heart disease. The discovery could lead to new treatments to prevent heart disease particularly in people with type 2 diabetes and the elderly.

30 May 2011

Ultra bad cholesterol

Bad cholesterol, known as LDL is known to be sticky but this ultra –bad called MGmin-LDL is found to be stickier meaning it's more likely to attach to arterial walls. This is more dangerous because when LDL attaches to artery walls it forms fatty plaques that cause coronary heart disease (CHD). As fatty plaques grow, they narrow the arteries and reduce blood flow and also may trigger a stroke or heart attack. CHD is the most common type of heart disease and kills almost 450,000 Americans each year.

29 May 2011

VeraLight's Scout DS Device receives Health Canada License approval

VeraLight Inc., a privately held medical device company, based here, today announced its Scout DS Device was granted a Health Canada Medical Device Licence for non-invasive diabetes screening.

27 Apr 2011

Study: People who have survived diabetes for many decades exhibit few complications

Over time, diabetes can wreak havoc on the body's eyes, cardiovascular system, kidneys and nerves. A major study by Joslin Diabetes Center researchers, however, has found that some people who have survived diabetes for many decades exhibit remarkably few complications—a discovery that points toward the presence of protective factors that guard against the disease's effects.

31 Mar 2011

HbA1c can be deceptive in African American children with diabetes: Study

Researchers at LSU Health Sciences Center New Orleans and Children's Hospital of New Orleans have found that there is a major difference in the hemoglobin A1c response to blood glucose between African-American and Caucasian children with diabetes. HbA1c is the main test used to monitor diabetes and guide treatment decisions.

5 May 2010

Wellness Formulations introduces Dermal Renu Sunshield

Wellness Formulations, LLC, a leader in anti-glycation research and product development, has launched Dermal Renu® Sunshield daily wear SPF 15 sunscreen. This mineral based sunscreen provides broad-spectrum protection from sun damage caused by UVA/UVB rays, while fighting the signs of aging through a unique combination of anti-glycation agents, antioxidants, moisturizing elements, peptides, and botanical extracts.

30 Mar 2010

New nutrition product to address effects of Glycation

After an extensive on going research program, Mineral BioSciences LLC a division of Global Organics Group is proud to announce the introduction of TOTALA® Nutrients, an ingredient that promises to have a profound effect on the nutrition industry.

8 Mar 2010

Wellness Formulations launches Dermal Renu Anti-Aging Skincare System

Wellness Formulations, LLC, a leading manufacturer in the development of innovative health and wellness products, has launched Dermal Renu® Advanced Skin Science, a new anti-aging skincare system designed for women of all ages seeking to achieve healthy, younger-looking skin.

5 Jan 2010

New technique may help diagnose treatments for Alzheimer's, diabetes and cancer

Chemists and biologists from the University of Bath have developed a new technique that could be used to diagnose and develop treatments for age-related conditions like Alzheimer's disease, diabetes and cancer.

15 Dec 2009

Avoiding foods high in AGE toxins can reduce inflammation and restore the body's natural defenses

Researchers from Mount Sinai School of Medicine report that cutting back on the consumption of processed and fried foods, which are high in toxins called Advanced Glycation End products (AGEs), can reduce inflammation and actually help restore the body's natural defenses regardless of age or health status. These benefits are present even without changing caloric or nutrient intake.

4 Nov 2009

Cutting back on the consumption of AGEs can reduce inflammation, report researchers

4 Nov 2009

Haber’s Electromolecular Propulsion technology offers high molecular separation speeds

Haber, Inc. (“Haber”), (OTC: HABE), a Delaware corporation headquartered in Arlington, Mass., with proprietary technologies in the separations sciences and environmentally friendly processing of gold bearing ores, announced today that it has formed a wholly owned subsidiary incorporated in Delaware called “EMP Diagnostics Inc.” (“EDI”). The business of the new company will focus on the application of Haber’s Electromolecular Propulsion technology (EMP). EMP is a separation technology that achieves unrivaled molecular separation speeds and has other unique capabilities not attainable with electrophoresis or liquid chromatography.

27 Aug 2009